# BirchBioMed Inc. — capital_raise/private_placement [announced]
Source: SEC API (secapi.ai) · situation sit_a0f84adb90ed25af830d · retrieved 2026-08-16T21:13:08.226Z

## Overview
BirchBioMed Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for scarring (fibrosis), certain autoimmune diseases (Type 1 Diabetes and Alopecia Areata), and organ fibrosis, with lead candidates FS2 (kynurenic acid) and AI-001 (antigen-presenting cells combined with FS2).

BirchBioMed Inc., a clinical-stage biopharmaceutical company developing treatments for scarring and autoimmune diseases, is conducting a direct listing on the Nasdaq Global Market under the symbol "BRBM." The company is registering the resale of up to 29,925,851 common shares by existing shareholders (Registered Shareholders), with no firm-commitment underwriting. Unlike a traditional IPO, the Registered Shareholders may elect to sell their shares at prevailing market prices or negotiated prices, and the company will not receive proceeds from these sales. The direct listing is contingent on Nasdaq approval of the listing application.

## Terms
- Counterparty: Nasdaq Global Market · Consideration: stock

## Key dates
- Announced 2026-08-12

## Timeline
- 2026-08-12 · S-1 (0001493152-26-037435): S-1 - BirchBioMed Inc. — *BirchBioMed Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for scarring (fibrosis), certain autoimmune diseases (Type 1 Diabetes and Alopecia Areata), and organ fibrosis, with lead candidates FS2 (kynurenic acid) and AI-001 (antigen-presenting cells combined with FS2).* BirchBioMed Inc., a clinical-stage biopharmaceutical company developing treatments for scarring and autoimmune diseases, is conducting a direct listing on the Nasdaq Global Market under the symbol "BRBM." The company is registering the resale of up to 29,925,851 common shares by existing shareholders (Registered Shareholders), with no firm-commitment underwriting. Unlike a traditional IPO, the Registered Shareholders may elect to sell their shares at prevailing market prices or negotiated prices, and the company will not receive proceeds from these sales. The direct listing is contingent on Nasdaq approval of the listing application.
  https://www.sec.gov/Archives/edgar/data/1670747/0001493152-26-037435.txt

## Citations
- 0001493152-26-037435 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000149315226037435